Senekowitsch-Schmidtke R - Search Results

1

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C. Knör S, et al. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. doi: 10.1007/s00259-007-0582-3. Epub 2007 Sep 22. Eur J Nucl Med Mol Imaging. 2008. PMID: 17891393

2

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Buchhorn HM, et al. Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. doi: 10.1007/s00259-006-0311-3. Epub 2007 Jan 6. Eur J Nucl Med Mol Imaging. 2007. PMID: 17206415

3

Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.

Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Pfost B, et al. J Nucl Med. 2009 Oct;50(10):1700-8. doi: 10.2967/jnumed.109.065961. J Nucl Med. 2009. PMID: 19793735 Free article.

4

177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.

Seidl C, Zöckler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. Seidl C, et al. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):312-22. doi: 10.1007/s00259-010-1639-2. Epub 2010 Nov 12. Eur J Nucl Med Mol Imaging. 2011. PMID: 21072513

5

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Essler M, Gärtner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, Bruchertseifer F, Morgenstern A, Seidl C. Essler M, et al. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):602-12. doi: 10.1007/s00259-011-2023-6. Epub 2012 Jan 12. Eur J Nucl Med Mol Imaging. 2012. PMID: 22237842

6

High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.

Rauch C, Seidl C, Schlapschy M, Skerra A, Morgenstern A, Bruchertseifer F, Senekowitsch-Schmidtke R. Rauch C, et al. Nucl Med Biol. 2012 Jul;39(5):617-27. doi: 10.1016/j.nucmedbio.2011.12.005. Epub 2012 Mar 3. Nucl Med Biol. 2012. PMID: 22381781

7

Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.

Vallon M, Seidl C, Blechert B, Li Z, Gilbertz KP, Baumgart A, Aichler M, Feuchtinger A, Gaertner FC, Bruchertseifer F, Morgenstern A, Walch AK, Senekowitsch-Schmidtke R, Essler M. Vallon M, et al. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1886-97. doi: 10.1007/s00259-012-2203-z. Epub 2012 Aug 8. Eur J Nucl Med Mol Imaging. 2012. PMID: 22872310

8

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Seidl C, Schröck H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Seidl C, et al. Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85. doi: 10.1007/s00259-004-1653-3. Epub 2004 Oct 2. Eur J Nucl Med Mol Imaging. 2005. PMID: 15791436

9

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Bloechl S, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s. doi: 10.1158/1078-0432.CCR-1004-0017. Clin Cancer Res. 2005. PMID: 16203804

10

Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells.

Stöber B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Stöber B, et al. Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):932-9. doi: 10.1007/s00259-005-0047-5. Epub 2006 Apr 8. Eur J Nucl Med Mol Imaging. 2006. PMID: 16604346

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

81 results

Search Page